Your browser doesn't support javascript.
loading
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai, Takako; Iwasa, Satoru; Hashimoto, Hironobu; Ohyanagi, Fumiyoshi; Takiguchi, Tomomi; Takeda, Koji; Nakao, Masahiko; Sakai, Hiroshi; Nakayama, Toshiaki; Minato, Koichi; Arai, Takahiro; Suzuki, Kenichi; Shimada, Yasuhiro; Nagashima, Kengo; Terakado, Hiroyuki; Yamamoto, Noboru.
Affiliation
  • Yanai T; Department of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Iwasa S; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Hashimoto H; Department of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Ohyanagi F; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Takiguchi T; Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Takeda K; Department of Medical Oncology, Osaka City General Hospital, 2-13-22, Miyakojimahondohri, Miyakojima-ku, Osaka, 534-0021, Japan.
  • Nakao M; Department of Pharmacy, Osaka City General Hospital, 2-13-22, Miyakojimahondohri, Miyakojima-ku, Osaka, 534-0021, Japan.
  • Sakai H; Division of Thoracic Oncology, Saitama Cancer Center, 780, Komuro, Ina, Kitaadachi, Saitama, 362-0806, Japan.
  • Nakayama T; Division of Pharmacy, Saitama Cancer Center, 780, Komuro, Ina, Kitaadachi, Saitama, 362-0806, Japan.
  • Minato K; Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi-cho, Ohta, Gunma, 373-0828, Japan.
  • Arai T; Division of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi-cho, Ohta, Gunma, 373-0828, Japan.
  • Suzuki K; Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Shimada Y; Clinical Oncology Division, Kochi Health Sciences Center, 2125-1, Ike, Kochi, Kochi, 781-8555, Japan.
  • Nagashima K; Department of Global Clinical Research, Graduate School of Medicine, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba, 260-8670, Japan.
  • Terakado H; Department of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. nbryamam@ncc.go.jp.
Int J Clin Oncol ; 23(2): 382-388, 2018 Apr.
Article in En | MEDLINE | ID: mdl-29039073
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vomiting / Benzodiazepines / Antiemetics / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country: Japan Country of publication: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vomiting / Benzodiazepines / Antiemetics / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country: Japan Country of publication: Japan